RiverCreek Therapeutics is advancing Egafusp™, a first-in-class inhaled biologic designed to address the large and growing global burden of allergic rhinitis and other IgE-mediated allergic diseases.
With a differentiated mechanism, scalable inhaled delivery, and broad expansion potential, Egafusp represents a compelling opportunity for strategic partners and long-term supporters.
Allergic rhinitis is one of the most prevalent chronic immune-mediated conditions worldwide, affecting hundreds of millions of patients and driving a rapidly expanding therapeutic market.
With a differentiated mechanism, scalable inhaled delivery, and broad expansion potential, Egafusp represents a compelling opportunity for strategic partners across the healthcare ecosystem.
Inhaled Biologics: A New Market Segment
Egafusp is positioned as a first-in-class inhaled biologic, opening a new therapeutic segment within the allergic rhinitis market.
40–60 million people affected
~10–15% of the population
U.S. Anti-Allergy Biologics
$11B (2024)
Projected to reach $21.2B by 2034
~400 million people affected
~10–40% of the population
Global Anti-Allergy Biologics
$23B (2023)
Projected to reach $42.5B by 2033
Global Inhaled Anti-Allergy Biologics
Estimated 1–5% market penetration
$0.4–2.1B in annual sales potential (2033)
Inhaled biologics represent an emerging segment within allergy treatment, driven by a large unmet need for therapies that are both effective and convenient for patients. The United States is the largest commercial market for allergic rhinitis therapies, with global demand continuing to grow. Based on conservative adoption assumptions, a differentiated inhaled biologic with clear clinical and ease-of-use advantages could achieve approximately 1–5% penetration of the global allergic rhinitis market, translating to estimated annual sales of $0.43–2.1 billion by 2033.
Egafusp is designed to improve how allergic diseases are treated by delivering medicine directly to where symptoms start.
Inhaled biologic targeting IgE-driven allergy pathways
To inflamed nasal and airway tissues
With reduced whole-body exposure
Without injections or clinic visits
These advantages are making Egafusp treatment both effective and convenient for patients.